Kelly Bree, M.D.

Peer-Reviewed Articles

1. Toumazos K, Bell S, Spencer K, Nakagawa D, Bree KK, Kamat AM, Psutka SP, Hensley PJ. Patient Reported Outcomes as Non-Muscle Invasive Bladder Cancer Clinical Trial Endpoints. BJUI. e-Pub 2026.
2. Soliman C, Sathianathen N, Corcoran NM, Wuethrich PY, Furrer MA, Group Collaborators CS. International Multicentre Analysis of Perioperative Complications Following Major Urologic Oncologic Surgery: Early Results from More than 130 000 Procedures from the CAMUS Collaborative. Eur Urol Focus, 2026. e-Pub 2026. PMID: 42128799.
3. MacDonald LP, Kypriotakis G, Karam-Hage M, Minnix JA, Beneventi D, Cui Y, Blalock JA, Robinson JD, Alhalabi O, Hassanazadeh CJ, Lee BH, Navai N, Kamat AM, Dinney CP, Cinciripini PM, Bree KK. Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. Eur Urol Oncol, 2026. e-Pub 2026. PMID: 42236415.
4. Yu K, Chen J, Chu Y, Nair S, Crupi E, Hasanov E, Mei Y, Han X, Liu Y, Liu Y, Pei G, Peng F, Liao J, Dai E, Chu T, Cho KS, Jiang J, Yan X, Dai Y, Wang J, Zhang B, Genovese G, Putluri N, Eberlin L, Yang L, Lin C, Kwong LN, Shamsutdinova D, Wani KM, Czerniak BA, Yu W, Zhao J, Guo CC, Hansel D, Pettaway C, Pisters L, Bree K, Navai N, Lee BH, Kamat AM, Sharma P, Corn P, Jiang CY, Shah AY, Alhalabi O, Msaouel P, Siefker-Radtke AO, Logothetis CJ, Campbell MT, Lazar AJ, Gao J, Wang L. A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. Cancer Discov, 2026. e-Pub 2026. PMID: 42126225.
5. Soliman, C, Sathianathen, NJ, Corcoran, NM, Lawrentschuk, N, Wuethrich, PY, Furrer, MA, Ali, FA, Shah Bin Abd Karim, MF, Abouelenein, M, Ghanem, YA, Adam, A, Adami, A, Adamos, K, Adamou, C, Adeyeye, A, Aellen, F, Afferi, L, Agarwal, A, Agarwal, DK, Agarwal, V, Agostini, E, Agrawal, M, Agüera Sánchez, MÁ, Ahmad, S, Ahour, RT, Akbarov, I, Akbas, S, Akdogan, N, Aksaray, EE, Al-Bermani, O, Al-Monajjed, R, Al-Rammahi, D, Albala, DM, Albers, P, Albertsen, PC, Albuheissi, S, Ali, HA, Ibrahim Ali Mohsen, MA, Almarzouq, A, Altaylouni, T, Ambulkar, R, Bree, KK, Cata, JP, Dinney, CP, Gottumukkala, V, Haque, S, Lasala, J, Navai, N, Popat, KU, Shah, JB. The CAMUS Initiative. European Urology Open Science 87:57-70, 2026. e-Pub 2026. PMID: 42003843.
6. Myers, AA, Duan, Z, Igel, DA, Steinmetz, AR, Grajales, V, Bree, KK, Zhao, H, Giordano, SH, Kamat, A. Disparities and temporal trends in referral for bladder cancer diagnosis. Urologic Oncology: Seminars and Original Investigations 44(2):120.e1-120.e11, 2026. e-Pub 2026. PMID: 41381259.
7. Myers, AA, Talwar, R, Duan, Z, Hensley, PJ, Lotan, Y, Williams, SB, Luckenbaugh, AN, Li, R, Kassouf, W, Necchi, A, Packiam, V, Shore, ND, Steinberg, GD, Witjes, JA, Schmidt, B, Porten, S, Hahn, NM, Bree, KK, Toumazis, I, Zhao, H, Kamat, A. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder. European urology 89(2):151-162, 2026. e-Pub 2026. PMID: 41046180.
8. Carriere P, Alhalabi O, Gao J, Shah A, Goswami S, Campbell M, Lin R, Mayo L, Mohamad O, Hoffman K, Mok H, Lozano C, Kamat A, Navai N, Bree K, Lee B, Guo C, Rooney M, Tang C, Choi S, Hassanzadeh C. Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract. Bladder Cancer, 2026. e-Pub 2026. PMID: 41550986.
9. Lobo, N, Lobo, N, Duan, Z, Duan, Z, Sood, A, Sood, A, Zhao, H, Zhao, H, Lindskrog, SV, Lindskrog, SV, Dyrskjøt, L, Dyrskjøt, L, Giordano, SH, Giordano, SH, Williams, SB, Williams, SB, Bree, KK, Bree, KK, Kamat, A, Kamat, A. Sex Disparity in Non-muscle-invasive Bladder Cancer. European Urology Oncology 8(3):608-611, 2025. e-Pub 2025. PMID: 39448349.
10. Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
11. Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskjøt L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?. Eur Urol Oncol 7(5):1069-1079, 2024. e-Pub 2024. PMID: 38302322.
12. Bree, KK, Janes, JL, Hensley, PJ, Srinivasan, A, De Hoedt, AM, Das, S, Freedland, S, Williams, SB. Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system. BJU International 134(3):473-483, 2024. e-Pub 2024. PMID: 38680113.
13. Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, Kamat AM. Influence of Lamina Propria Invasion Extension on T1 High-grade Non-muscle-invasive Bladder Cancer in Patients Undergoing BCG or Radical Cystectomy. BJU Int 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
14. Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-term Oncological Outcomes in Patients Diagnosed with Non-metastatic Plasmacytoid Variant of Bladder Cancer: A 20-year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):241-255, 2024. e-Pub 2024. PMID: 37922370.
15. Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of Age >70 Years on Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. BJU Int 133(1):63-70, 2024. e-Pub 2024. PMID: 37442564.
16. Contieri R, Hensley PJ, Tan WS, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
17. Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Guérin (BCG) Unresponsive Non-Muscle-Invasive Bladder Cancer: Are the Subgroups Equal?. BJU Int 132(4):384-386, 2023. e-Pub 2023. PMID: 37246493.
18. Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol 6(5):531-534, 2023. e-Pub 2023. PMID: 37468392.
19. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
20. Faulk A, Avulova S, Bree KK, Baak-Kukreja J, Westerman ME. Pelvic Organ Preservation in Non-muscle Invasive Bladder Cancer: Less is More. Eur Urol Focus S2405-4569(23):00103-7, 2023. e-Pub 2023. PMID: 37142535.
21. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-Muscle-Invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 13(53):16-22, 2023. e-Pub 2023. PMID: 37441349.
22. Wang XS, Bree KK, Navai N, Kamal M, Shen SE, Letona E, Cleeland CS, Shi Q, Gottumukkala V. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37297013.
23. Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk from Second Primary Malignancy in Bladder Cancer Patients following Radical Cystectomy: Implications for Survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
24. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
25. Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological Analysis and Outcomes of Inflammatory Myofibroblastic Tumours of the Urinary Bladder. BJU Int 130(5):604-610, 2022. e-Pub 2022. PMID: 34773684.
26. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should Patients with Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors during Bacille Calmette-Guérin?. BJU Int 130(4):463-469, 2022. e-Pub 2022. PMID: 34854189.
27. Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
28. Escott M, Avulova S, Bree K, Westerman ME. Radical Cystectomy and Women's Sexual Health - Can we do Better?. Curr Opin Urol 32(5):545-553, 2022. e-Pub 2022. PMID: 35916011.
29. Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced-dose Bacillus Calmette-Guérin (BCG) in an Era of BCG Shortage: Real-world Experience from a Tertiary Cancer Centre. BJU Int 130(3):323-330, 2022. e-Pub 2022. PMID: 34847263.
30. Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
31. Kamal M, Navai N, Bree KK, Williams LA, Cleeland CS, Shen SE, Wang XS. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. Cancers (Basel) 16(14):3896, 2022. e-Pub 2022. PMID: 36010890.
32. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2022. PMID: 33935020.
33. Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated with Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open 5(3):e223050, 2022. e-Pub 2022. PMID: 35302627.
34. Bree KK, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply. J Urol 207(2):476-477, 2022. e-Pub 2022. PMID: 34694162.
35. Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2022. PMID: 34920986.
36. Hensely PJ, Lobo N, Bree KK, Tan WS, Gontero P, Williams SB, Guo CG, Giannarini G, Dyrskjot L, Kamat AM. Predictive Biomarkers in the Management of Bladder Cancer: Perspective in an Evolving Therapeutic Landscape. Societe Internationale d'Urologie Journal 3(4):245-257, 2021. e-Pub 2021.
37. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CPN, Kamat AM. Impact of Upper Tract Urothelial Carcinoma on Response to BCG in Patients with Non-Muscle-Invasive Bladder Cancer. BJU Int 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
38. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
39. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):1258-1267, 2021. e-Pub 2021. PMID: 34184926.
40. Bree KK, Hensley PJ, Brooks N, Matulay J, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Impact of Sex on Response to BCG in Non-Muscle Invasive Bladder Cancer Patients: A Contemporary Review from a Tertiary Care Center. World J Urol 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
41. Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology 157:181-187, 2021. e-Pub 2021. PMID: 34186127.
42. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumour to Bacille Calmette-Guérin Induction does not Impact Therapeutic Response. BJU Int 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
43. Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
44. Panizzon MS, Bree K, Hsieh T, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic Variation in the Androgen Receptor Modifies the Association Between Testosterone and Vitality in Middle-Aged Men. J Sex Med, 2020. e-Pub 2020. PMID: 33011098.
45. Bree KK, Matin SF. The Remaining Ipsilateral Ureteral Orifice Provokes Intravesical Tumor Recurrence after Nephrouretectomy of Upper Tract Urothelial Carcinoma: A Multicenter Study with a Mid-term Follow-up. Urology:145:171. doi: 10.1016/j.urology.2020.06.086, 2020. e-Pub 2020. PMID: 32791287.
46. Ghali F, Elbakry AA, Hamilton ZA, Yik K, Nassrei R, Patel S, Eldefrawy A, Ryan S, Bradshaw AW, Meagher M, Bree K, Reddy M, Lee HJ, Derweesh IH. Robotic Partial Nephrectomy for Clinical T2a Renal Mass is Associated with Improved Trifecta Outcome Compared to Open Partial Nephrectomy: A Single Surgeon Comparative Analysis. World J Urol 38(5):1113-1122, 2020. e-Pub 2020. PMID: 31701211.
47. Panizzon MS, Bree K, Hsieh C, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic Variation in the Androgen Receptor Modifies the Association between Testosterone and Vitality in Middle-aged Men. J Sex Med 17(12):2351-2361, 2020. e-Pub 2020. PMID: 33011098.
48. Gaylis F, Bree KK, Dato P, Andriole GL, Kane CJ, Kader AK. Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples from Clinical Practice. Rev Urol 22(4):152-158, 2020. e-Pub 2020. PMID: 33927572.
49. Patel SH, Panian J, Bree K, Derweesh I, Millard F, Randall J, Mckay R. Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. Eur Urol Focus 6(1):17-25, 2020. e-Pub 2020. PMID: 31255618.

Review Articles

1. Li, R, Hensley, PJ, Babjuk, M, Bukavina, L, Psutka, SP, Lerner, SP, O'Donnell, M, Lotan, Y, Bree, KK, Redorta, JP, McConkey, DJ, Lee, B, Mariappan, P, Mertens, LS, Soloway, M, Svatek, RS, Tan, WS, Williams, SB, Gupta, S, Buckley, R, Kamat, A. Intermediate-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology 8(6):1685-1695, 2025. e-Pub 2025. PMID: 41076366.
2. MacDonald, LP, Smith, MR, Bree, KK. New Paradigms for Bladder Cancer Management in Geriatrics. Clinics in Geriatric Medicine 41(2):175-185, 2025. e-Pub 2025. PMID: 40345772.
3. Li, R, Hensley, PJ, Gupta, S, Al Ahmadie, H, Babjuk, M, Black, P, Brausi, M, Bree, KK, Fernandez, M, Guo, CC, Horowitz, A, Lamm, DL, Lerner, SP, Lotan, Y, Mariappan, P, McConkey, D, Mertens, LS, Mir, C, Ross, JS, O'Donnell, M, Palou, J, Pohar, KS, Steinberg, GD, Soloway, M, Spiess, PE, Svatek, RS, Tan, WS, Taoka, R, Buckley, R, Kamat, A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European urology 86(6):516-527, 2024. e-Pub 2024. PMID: 39183090.
4. Bree KK, Hensley PJ, Pettaway CA. Germline Mutations in African American Men with Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology 163:148-155, 2022. e-Pub 2022. PMID: 34453957.
5. Bree, KK, Henley, PJ, Pettaway, CA. Germline Predisposition to Prostate Cancer in Diverse Populations. Urologic Clinics of North America 48(3):411-423, 2021. e-Pub 2021. PMID: 34210495.
6. Bree, KK, Brooks, NA, Kamat, A. Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America 35(3):513-529, 2021. e-Pub 2021. PMID: 33958148.
7. Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. Germline Genetics in Localized Prostate Cancer. Curr Opin Urol 29(4):326-333, 2019. e-Pub 2019. PMID: 31116139.
8. Bree KK, Whicker SA, Fromme H, Paik S, Greenberg L. Residents-as-Teachers Publications: What Can Programs Learn From the Literature When Starting a New or Refining an Established Curriculum?, 2014. e-Pub 2014. PMID: 24949126.

Professional Educational Materials

1. Bree KK, Koehne E, Matulewicz RS, Morgans AK, Packiam VT, Tabayoyong B. Cancer Survisorship, 2025.
2. Bree KK, Whicker SA, Fromme HB, Paik S, Greenberg L. What Can Programs Learn from the Literature When Starting a New or Refining an Established Curriculum. Residents as Teachers (RAT), 2014.

Editorials

1. Kamat AK, Hensley PJ, Bree KK. Occult Nodal Metastases in Patients Down-staged to Non-Muscle Invasive Disease Following Neoadjuvant Chemotherapy. In Practice Update, 2020. PMID: 32268173.

Abstracts

1. Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore ND, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM. Updated Analysis of Cost-Effectiveness Among Bladder Sparing Treatments for BCG-Unresponsive CIS: Incorporating Recently Approved and Established Therapies. American Urological Association Annual Meeting 2026 (AUA 2026) 215(5S):e1482, 2026. e-Pub 2026.
2. McGonagle K, Ellis TA, Ellis E, Cotta BH, Bree K. Persistent Gender Disparities in Urologic Oncology: Trends in Urology Residency and Urologic Oncology Fellowship Match Among Female Trainees. American Urological Association Annual Meeting 2026 (AUA 2026) 215(5S):e1607, 2026. e-Pub 2026.
3. Patel S, Li Z, Black J, Qiao W, Rauf M, Lee T, Bree K, Guo C, Lee B, Dinney C, Navai N, and Kamat A. Prognostic Outcomes Comparing Upfront Radical Cystectomy and Primary BCG Therapy in Very-High Rick Non-muscle Invasive Bladder cancer: An Updated analysis in the Modern BCG Era. American Urological Association Annual Meeting 2026 (AUA 2026) 215(5S):e62, 2026. e-Pub 2026.
4. Goradia RR, Sundi D, Lee CT, Dason S, Singer EA, Abdollah F, Stephens A, Bree K, Hensley P, Martini A, Sood A. Germline Mutations and Demographic Differences in Pure Urothelial Cancer. American Urological Association Annual Meeting 2026 (AUA 2026) 215(5S):e726, 2026. e-Pub 2026.
5. Das A, Wisdom E, Rauf M, Sanchez D, MacDonald L, Panchapakesan K, Hwang H, Zhang M, Colbert L, Choi S, Johns A, Czerniak B, Change C, Zacharias NM, Campbell M, Kamat A, Bree K, Pettaway C. Contemporary Management of Advanced Urethral Cancer: The Effect of Preoperative Chemotherapy or Radiation When Combined With Surgery. American Urological Association Annual Meeting 2026 (AUA 2026) 215(5S):e851, 2026. e-Pub 2026.
6. MacDonald L, Kypriotakis G, Karam-Hage M, Minnix JA, Beneventi D, Cui Y, Blalock JA, Robinson JD, Alhalabi O, Hassanzadeh CJ, Lee BH, Navai N, Kamat AM, Dinney CP, Cinciripin PM, Bree K. Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025) 3, 2026. PMID: 42236415.
7. MacDonald L, Jackson J, Lawen T, Kouzy R, Colbert L, Zhang M, Czerniak B, Pettaway C, Bree K. Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy. 104th Annual Meeting of the South Central Section of the AUA (SCS AUA 2025), 2025.
8. Myers AA, Duan Z, Igel DA, Steinmetz AR, Grajales V, Bree KK, Zhao H, Giordano SH, Kamat AM. Disparities and Temporal Trends in Referral for Bladder Cancer Diagnosis: A Worsening Epidemic. American Urological Association Annual Meeting 2025 (AUA 2025) 213(5S):e248, 2025. e-Pub 2025. PMID: 41381259.
9. MacDonald L, Manuel CM, Qiao W, Lee B, Navai N, Kamat A, Dinney CP, Bree KK. Assessment of Intra and Postoperative Complications in Females Following Radical Cystectomy With and Without Gynecologic Organ Sparing. American Urological Association Annual Meeting 2025 (AUA 2025) 213(5S):e1276, 2025. e-Pub 2025.
10. Lee T, Myers A, Bree KK, Lee BH, Navai N, Guo CC, Alhalabi O, Dinney CP, Kamat AM. Clinicopathologic Characteristics and Outcomes of Young Onset Bladder Cancer: A Single-Center Experience. American Urological Association Annual Meeting 2025 (AUA 2025) 213(5S):e249, 2025. e-Pub 2025.
11. Myers AA, Kontoyiannis P, Jackson JC, Steinmetz AR, Lee T, Bree KK, Navai N, Lee BH, Pettaway C, N Dinney CP, Kamat AM. Urothelial Carcinoma of the Prostate and Intravesical Therapy: A Cautionary Tale. 25th Annual Meeting of the Society of Urologic Oncology (SUO 2024), 2024. e-Pub 2024.
12. Myers AA, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, N Dinney CP, Kamat AM. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?. American Urological Association Annual Meeting 2024 (AUA 2024) 86(4):366-368, 2024. e-Pub 2024. PMID: 38879371.
13. Kontoyiannis P, Myers AA, Jackson JC, Steinmetz AR, Bree KK, Navai N, Lee BH, Pettaway C, Dinney CP, Kamat AM. Urothelial Carcinoma of the Prostate and Intravesical Therapy: A Cautionary Tale. 103rd Annual Meeting of the South Central Section of the AUA (SCS AUA 2024), 2024. e-Pub 2024.
14. Myers AA, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, N Dinney CP, Kamat AM. Elucidating the Response Rates to Continued Bacillus Calmette-Guerin (BCG) in Patients with BCG Exposed Bladder Cancer: Implications for Clinical Trial Design. American Urological Association Annual Meeting 2024 (AUA 2024) 211(5S):e627, 2024. e-Pub 2024.
15. Myers AA, Steinmetz AR, Grajales V, Bree KK, Duan Z, Makaraoff L, Kamat AM. Females with Bladder Cancer are Underrepresented in Clinical Trials in the United States. American Urological Association Annual Meeting 2024 (AUA 2024) 211(5S):p e1135, 2024. e-Pub 2024.
16. Bree K, Janes J, Hensley P, Srinivasan A, DeHoedt A, Das S, Freedland S, Williams S. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in the Largest Equal Access Health System in the US: The VA Health System. 102nd Annual Meeting of the South Central Section of the AUA (SCS AUA 2023), 2023.
17. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Navai N, Dinney C, Kamat A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. American Urological Association Annual Meeting 2023 (AUA 2023) 13(53):16-22, 2023. e-Pub 2023. PMID: 37441349.
18. Lim A, Sood A, Narayan V, Seif M, Matulay J, Bree K, Campbell M, Kamat A, Dinney C, Navai N. Pathologic Downstaging Rate and Predictive Biomarker Exploration in Patients with Biopsy-Proven Clinical Node Positive Bladder Cancer Undergoing Chemotherapy Followed by Radical Cystectomy. American Urological Association Annual Meeting 2023 (AUA 2023) 209(4S):e775, 2023. e-Pub 2023.
19. Bree K, Janes J, Yang R, Hensley P, Srinivasan A, DeHoedt A, Das S, Freedland S, Williams S. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in the Largest Equal Access Health System in the US: The Veterans Affairs Health System. American Urological Association Annual Meeting 2023 (AUA 2023) 209(4S):e828, 2023. e-Pub 2023.
20. Contieri R, Tan WS, Grajales V, Bree K, Hensley P, Guo CC, Navai N, Dinney CP, Kamat AM. T1 Sub-Staging is Associated with Worse Oncological Outcomes for Patients Treated with Bacillus Calmette-Guerin or Immediate Radical Cystectomy. American Urological Association Annual Meeting 2023 (AUA 2023) 209(4S):e877, 2023. e-Pub 2023.
21. Contieri R, Grajales V, Tan WS, Bree K, Hensley P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Advanced Age (>70 years) Does Not Affect Oncological Outcomes in Non-Muscle Invasive Bladder Cancer patients Treated with Adequate Bacillus Calmette-Guerin: A Competing Risk Analysis From a Tertiary Care Center. American Urological Association Annual Meeting 2023 (AUA 2023) 209(4S):e875, 2023. e-Pub 2023.
22. Contieri R, Hensley P, Tan WS, Grajales V, Bree K, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bacillus Calmette-Guerin vs Immediate Radical Cystectomy in EAU Defined Very High-Risk Non-Muscle Invasive Bladder Cancer Patients. American Urological Association Annual Meeting 2023 (AUA 2023) 209(4S):e873, 2023. e-Pub 2023.
23. Long D, Janes J, Yang R, Williamson E, Bree K, Srinivasan A, Dehoedt A, Freedland S, Williams S. Understanding the Impact of the Social Construct of Race on Receipt of Radical Cystectomy in the Largest Equal Access Health System in the US: The Veterans Affairs Health System. American Urological Association Annual Meeting 2023 (AUA 2023) 209(Supplement 4):e630, 2023. e-Pub 2023.
24. Sood A, Rudzinski J, Labbate C, Hensley P, Bree K, Guo C, Alhalabi O, Campbell M, Siefker-Radtke A, Navai N, Dinney C, Gao J, Kamat A. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. 23rd Annual Meeting of the Society of Urological Oncology (SUO 2022) 211(2):241-255, 2022. e-Pub 2022. PMID: 37922370.
25. Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. American Urological Association Annual Meeting 2022 (AUA 2022) 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
26. Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman H, Dinney CP, Kamat AM. Restaging Transurethral Resection of HG TA Urothelial Carcinoma: A Risk-Adapted Approach. 21st Annual Meeting of the Society of Urologic Oncology (SUO) - Virtual Meeting, 2022. e-Pub 2022. PMID: 33935020.
27. Hensley P, Lobo N, Bree K, Sood A, Navai N, Dinney C, Kamat A. Timing of Radical Cystectomy for BCG Failure. American Urological Association Annual Meeting 2022 (AUA 2022) 207(5S):e933, 2022. e-Pub 2022.
28. Bree K, Shan Y, Hensley P, Lobo N, Hu C, Tyler D, Chamie K, Kamat A, Williams S. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. American Urological Association Annual Meeting 2022 (AUA 2022), 2022. e-Pub 2022. PMID: 35302627.
29. Bree K, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Kamat A, Dinney C, Navai N. Repeat Transurethral Resection (Returbt) of Muscle Invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but not Therapeutic: A Propensity-Score Matched Analysis. 22nd Annual Meeting of the Society of Urologic Oncology, 2021. e-Pub 2021.
30. Hensley P, Duan Z, Bree K, Sood A, Kokorovic A, Zhao H, Guo C, Navai N, Dinney C, Kamat A. Competing Mortality in Bladder Cancer Patients After Cystectomy: The Role of Second Non-Urothelial Cancers. American Urological Association Annual Meeting 2021 (AUA 2021-Virtual) 206(3S):e909, 2021. e-Pub 2021.
31. Hensley P, Bree K, Brooks N, Matulay J, Li R, Nogueras-Gonzalez G, Nagaraju S, Navai N, Grossman H, Dinney C, Kamat A. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. American Urological Association Annual Meeting 2021 (AUA 2021-Virtual) 5(3):347-356, 2021. e-Pub 2021. PMID: 33935020.
32. Bree K, Hensley P, Brooks N, Xiao L, Shen Y, Navai N, Grossman H, Dinney C, Kamat A. A Novel Nomogram to Predict BCG Response in Patients with High-Grade Non-Muscle Invasive Bladder Cancer. American Urological Association Annual Meeting 2021 (AUA 2021-Virtual) 206(3S):e298, 2021. e-Pub 2021.
33. Hensley P, Bree K, Brooks N, Matulay J, Li R, González GN, Navai N, Grossman H, Dinney C, Kamat AM. Time Interval From Transurethral Resection to onset of BCG Induction Does Not Impact Therapeutic Response: Implications During Times of Impaired Access to Healthcare. 21st Annual Meeting of the Society of Urologic Oncology (SUO) - Virtual Meeting, 2020.
34. Westerman ME, Kokorovic A, Bree K, Wang XS, Lim A, Gonzalez AG, Wang R, Kamat AM, Dinney CP, Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. 21st Annual Meeting of the Society of Urologic Oncology (SUO) - Virtual Meeting, 2020. e-Pub 2020. PMID: 32713807.

Book Chapters

1. Grajales, V, Lange, S, Bree, KK. Bladder Cancer, 215-226, 2024.
2. Lange S, Grajales V, Bree K. Gynecologic Care of the Cancer Patient. In: Gynecologic Cancer. Cambridge Press, 2022.
3. Bree KK, Brooks NA, Kamat AM. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. In: Bladder Cancer. 35. Hematol Oncol Clin North Am, 513-529, 2021.
4. Bree KK, Hensley PJ, Pettaway CA. Germline Predisposition to Prostate Cancer in Diverse Populations. In: Urol Clin North Am. 3, 411-423, 2021.
5. Bree KK, Santiago-Lastra Y. Diabetic Cystopathy. In: Urologic Care for Patients with Progressive Neurological Conditions. Springer, 159-166, 2019.

Letters to the Editor

1. Myers, AA, Tan, WS, Grajales, V, Hwang, H, Bree, KK, Navai, N, Lee, B, Dinney, CP, Kamat, A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer. European urology 86: 366-368, 2024.
2. Bree, KK, Navai, N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 839, 2023.
3. Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Reply by Authors. Journal of Urology 208: 290-291, 2022.